Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8968430 | 0.85 | MEN1 (0.31) | PDE3BPDE3A | |
| SCHEMBL8968208 | 0.85 | PDE3B (0.31) | PDE3BPDE3A | |
| SCHEMBL8969583 | 0.81 | KDM4E (0.30) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL8969874 | 0.75 | KDM4E (0.30) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL8969217 | 0.75 | PDE3B (0.43) | PDE3BPDE3AKDM4EALDH1A1POLB | |
| SCHEMBL8969607 | 0.73 | KDM4E (0.31) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL8969165 | 0.73 | — | — | |
| SCHEMBL8969342 | 0.73 | — | — | |
| SCHEMBL8970477 | 0.73 | KDM4E (0.32) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL8969612 | 0.72 | PDE3B (0.34) | PDE3BPDE3AKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5486512-A | LEARNING ENHANCEMENT | WARNER-LAMBERT COMPANY (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1993003034-A1 | QUINAZOLINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-02-18 | — | — | WO | disclosed |